Asana Medical CEO Dr. Christine V. Sapan To Present At 2016 BIO International Convention June 8th

MIAMI LAKES, FL--(Marketwired - June 01, 2016) - Asana Medical, Inc., (“Asana,” the “Company”), an emerging life science company focused on the development and commercialization of its innovative tissue engineered therapy to treat Inflammatory Bowel Disease (“IBD”), is pleased to announce that CEO Dr. Christine V. Sapan will be presenting at the 2016 BIO International Convention, being held this year at the Moscone Center in San Francisco, CA from June 6th through June 9th. Dr. Sapan is scheduled to present at the Start-Up Stadium venue on June 8th between 11:00 am - 1:00 pm PT.

Asana’s product, ExtraCellular Matrix Hydrogel (“ECMH”), is a liquid derived from porcine tissue. Ulcerative Colitis, the disease to which Asana’s breakthrough technology will be first applied, is a debilitating disease that renders the colon dysfunctional. ECMH creates an environment favorable for the body to grow new tissue in place of diseased or damaged tissue. Extracellular matrix has been proven to be safe and effective in esophageal repair, hernia grafts, vaginal slings, and burn and wound dressings; Asana is leveraging this safe, proven technology to gastrointestinal applications.

Asana recently completed its pivotal preclinical rodent study. This report will be filed with regulatory authorities in support of Asana’s submission for approval to conduct its First-In-Human study. Dr. Sapan will discuss the results and proprietary interpretations during her presentation. For those interested in scheduling a one-on-one meeting with Dr. Sapan while at BIO International, please contact Asana Medical, Inc. at (844) 432-7262 extension 105.

ABOUT ASANA MEDICAL, INC.
Asana Medical, Inc. is an emerging life science company developing tissue engineered therapies for the treatment of Inflammatory Bowel Disease (IBD) and other GI diseases. The Company’s lead therapy, a novel application of a proven technology, will be a first-in-class therapy for patients suffering from Ulcerative Colitis. This therapy will be positioned to compete in a multi-billion dollar market dominated by biologic and drug therapies that can have significant side effects. Additionally, 20-30% of patients do not benefit from these therapies and have no alternative but to undergo colon removal surgery. Asana has an experienced management team, strong patent protection, world-class advisors in business and medicine, and compelling preclinical data.

For more information, visit www.asanamedical.com.

Download Executive Summary

Keep up-to-date on all of Asana’s news and developments, join our online communities:

Asana Medical - Facebook
Asana Medical - Twitter
Asana Medical - LinkedIn